The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Jobe AL, Ahonen KT, Poplin V, Rao S, Mohyuddin GR

Afatinib-induced Interstitial Lung Disease Successfully Treated with Corticosteroids: Case Report and Review of the Literature.

Cureus. 2018;10(6):e2805

Fujita K, Morishima Y, Aida Y, Tsunoda Y, Hida N, Shiozawa T, Nakazawa K, Sekine I, Hizawa N

Afatinib-Induced Severe Interstitial Lung Disease Successfully Treated with High-Dose Corticosteroid Therapy: A Case Report.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2017;12(2):e11-e13

Qi WX, Sun YJ, Shen Z, Yao Y

Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials.

Journal of chemotherapy (Florence, Italy). 2015;27(1):40-51